and in March this year for foetal neonatal alloimmune thrombocytopenia treatment. J&J Innovative Medicine Rheumatology and Immunology Disease Area leader and vice-president Terence Rooney said ...

Following Johnson & Johnson’s (J&J) recent US Food and Drug Administration (FDA) fast track designation of nipocalimab for the reduction of foetal and neonatal alloimmune thrombocytopenia (FNAIT ...

Neonatal alloimmune neutropenia (NAN) is a condition where a newborn's neutrophils, a type of white blood cell crucial for fighting infections, are destroyed by antibodies produced in response to ...

[2] Platelet destruction in the neonate can be from an immune response to antibodies in the neonatal circulation. In the following sections, autoimmune and alloimmune thrombocytopenia will be ...

In preterm babies, plasmatic coagulation becomes subject to a tendency to hemorrhage, and neonatal alloimmune thrombocytopenia (NAIT) may be present (3). Both should be considered on obstetric ...

In a poster titled "Prophylactic Administration of HPA-1a–Specific Antibody RLYB212 Safely Prevents Fetal/Neonatal Alloimmune Thrombocytopenia Due to HPA-1a Incompatibility in Pregnant Mice ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of ...